These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6820526)

  • 1. [Curves of factor VIII activity in the plasma of hemophiliacs after injection of 500 units of lyophilized factor VIII].
    Zanichelli M; Carelli Cde R; Coelho E; Salem MZ
    AMB Rev Assoc Med Bras; 1982; 28(11-12):261-3. PubMed ID: 6820526
    [No Abstract]   [Full Text] [Related]  

  • 2. [Suppression of factor VIII inhibitor in children with hemophilia A].
    Zenz W; Muntean W
    Padiatr Padol; 1987; 22(4):345-52. PubMed ID: 3125510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of factor VIII inhibitor in hemophiliacs].
    Mancini AF; Rosito P; Paolucci G
    Minerva Pediatr; 1976 Nov; 28(36):2181-5. PubMed ID: 995099
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of hemophiliacs with antibodies to factor VIII].
    Evensen SA; Stavem P; Stormorken H; Glomstein A; Ly B
    Tidsskr Nor Laegeforen; 1986 Jan; 106(1):35-8. PubMed ID: 3082032
    [No Abstract]   [Full Text] [Related]  

  • 6. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
    Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
    Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
    Stampfli K
    Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ; Dias Francisco F; Tavares ML; Leal I
    Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII competitive enzyme assay: observations in von Willebrand's variants and hemophiliacs.
    Yorde LD; Yorde DE; Sasse EA; Hussey CV
    Clin Physiol Biochem; 1984; 2(6):298-303. PubMed ID: 6440727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
    Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
    J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired circulating anticoagulants in hemophilia A.
    Strauss HS
    N Engl J Med; 1969 Oct; 281(16):866-73. PubMed ID: 5812255
    [No Abstract]   [Full Text] [Related]  

  • 16. [Perioperative management of orthopaedic patients with hemophilia A].
    Wu YG; Li XG; Zhang KN; Ren YJ; Li SF; Lu MY
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1430-3. PubMed ID: 15733456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the haemophiliac factor.
    Coutts AM
    Cent Afr J Med; 1997 Sep; 43(9):277-8. PubMed ID: 9509651
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
    Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.